RxDoctor Payments DataLook up a doctor →

Jeffery Tauth, MD

Interventional Cardiology · Hot Springs National Park, ARNPI 1437154036

Payments from drug & device makers

$6,560in general payments, 2019–2025

Across 332 payments — averaging $19.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$868
  • Amgen$804
  • Medtronic$732
  • Johnson & Johnson$622
  • Merck$467
  • AstraZeneca$440
  • plus $3K from 29 others

What the payments were for

  • Consulting fees$250%
  • Travel & lodging$1352%
  • Food & beverage$6,30096%
  • Education$992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,560 in reported general payments places this provider in the 40th percentile of 89 interventional cardiology providers in Arkansas.

See all interventional cardiology providers in Arkansas

Medicare billing

Part B allowed, 2024
$2,915,125
Medicare patients
1,219
Services billed
14,213

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan148$167,833
Repatha SureclickEvolocumab126$149,341
XareltoRivaroxaban105$101,235
EliquisApixaban84$67,064
Praluent PenAlirocumab29$35,654
Repatha PushtronexEvolocumab14$15,221
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide614$13,564
Ranolazine ErRanolazine158$10,394
Metoprolol Succinate827$9,744
SotalolSotalol Hcl441$8,814
Nebivolol Hcl131$7,553
ClopidogrelClopidogrel Bisulfate883$6,261
Bumetanide178$6,000
Propafenone Hcl141$5,142
Isosorbide Mononitrate ErIsosorbide Mononitrate341$5,086

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$868$167,833148 claims
Johnson & JohnsonXarelto$622$101,235105 claims
PfizerEliquis$70$67,06484 claims
AstraZenecaBrilinta$440$5,08312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 89 interventional cardiology providers in Arkansas.

Other interventional cardiology in Hot Springs National Park

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →